HNWAG
SYRE icon

High Net Worth Advisory Group’s Spyre Therapeutics SYRE Stock Holding History

High Net Worth Advisory Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$533K Hold
6,000
– – 0.11% 146
2026
Q1 		$303K Buy
+6,000
New +$226K 0.07% 194

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

High Net Worth Advisory Group's SYRE Position: Q2 2026 in Review

High Net Worth Advisory Group held its Spyre Therapeutics (SYRE) position steady in Q2 2026 at 6,000 shares worth $533K. The position accounts for 0.11% of the portfolio, ranked #146.

High Net Worth Advisory Group first reported a position in SYRE in Q1 2026 and has held it in 2 quarters since. 267 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • High Net Worth Advisory Group held 6,000 shares of Spyre Therapeutics worth $533K as of Q2 2026.
  • High Net Worth Advisory Group left its Spyre Therapeutics share count unchanged in Q2 2026.
  • Spyre Therapeutics made up 0.11% of High Net Worth Advisory Group's portfolio in Q2 2026, its #146 holding.
  • High Net Worth Advisory Group first reported a position in Spyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 267 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on High Net Worth Advisory Group's 13F filing for Q2 2026, filed 29 Jul 2026.